Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis.

[1]  P. Kawalec,et al.  Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis , 2022, Neurological Sciences.

[2]  E. Cristiano,et al.  Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina , 2022, Clinical neuropharmacology.

[3]  Jeffrey A. Cohen,et al.  Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II , 2022, Multiple sclerosis.

[4]  S. Sillau,et al.  Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis , 2022, Frontiers in Neurology.

[5]  B. Casanova,et al.  Escalation vs. Early Intense Therapy in Multiple Sclerosis , 2022, Journal of personalized medicine.

[6]  M. Filippi,et al.  Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis , 2021, Journal of Neurology.

[7]  G. Urrútia,et al.  Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas , 2021 .

[8]  V. Shaygannejad,et al.  Early predictors of conversion to secondary progressive multiple sclerosis. , 2021, Multiple sclerosis and related disorders.

[9]  B. Cree,et al.  Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. , 2021, Multiple sclerosis and related disorders.

[10]  Zhuoyi Liu,et al.  Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. , 2021, Autoimmunity reviews.

[11]  M. Rovaris,et al.  Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies , 2021, Therapeutic advances in neurological disorders.

[12]  P. Sørensen,et al.  Initial high-efficacy disease-modifying therapy in multiple sclerosis , 2020, Neurology.

[13]  M. Trojano,et al.  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study , 2020, The Lancet Neurology.

[14]  C. Gasperini,et al.  Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study , 2020, Neurotherapeutics.

[15]  Yanli Zhang,et al.  Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis , 2019, Journal of Neurology.

[16]  V. Tomassini,et al.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis , 2019, JAMA neurology.

[17]  Robert C Reiner,et al.  Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[18]  J. Lechner-Scott,et al.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis , 2019, JAMA.

[19]  A. Thompson,et al.  New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom , 2017, Multiple sclerosis.

[20]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[21]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[22]  Xiaobo Yang,et al.  Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. , 2014, The Cochrane database of systematic reviews.

[23]  Martin Duddy,et al.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model , 2014, BMJ Open.

[24]  S. Bae,et al.  International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.

[25]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[26]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.